CY1121279T1 - Ετεροκυκλικη ενωση - Google Patents

Ετεροκυκλικη ενωση

Info

Publication number
CY1121279T1
CY1121279T1 CY20191100202T CY191100202T CY1121279T1 CY 1121279 T1 CY1121279 T1 CY 1121279T1 CY 20191100202 T CY20191100202 T CY 20191100202T CY 191100202 T CY191100202 T CY 191100202T CY 1121279 T1 CY1121279 T1 CY 1121279T1
Authority
CY
Cyprus
Prior art keywords
compound
heterocycle
union
salt
medicament
Prior art date
Application number
CY20191100202T
Other languages
English (en)
Inventor
Shizuo Kasai
Takashi Nakahata
Asato Kina
Hideki Hirose
Takeshi Yamasaki
Tohru Yamashita
Yoichi Nishikawa
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1121279T1 publication Critical patent/CY1121279T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Παρέχονται μία ένωση η οποία έχει μία δράση ανταγωνιστή SSTR5 και χρήση της ένωσης ως ενός φαρμάκου. Συγκεκριμένα, παρέχονται μία ένωση η οποία παριστάνεται με τον ακόλουθο τύπο: όπου κάθε σύμβολο είναι όπως ορίζεται εδώ, ή ένα άλας αυτής, ένα φάρμακο που περιλαμβάνει την ένωση ή ένα άλας αυτής και χρήση της ένωσης ή ενός άλατος αυτής ως ενός παράγοντα για την προφύλαξη ή τη θεραπευτική αγωγή του σακχαρώδους διαβήτη.
CY20191100202T 2013-10-29 2019-02-14 Ετεροκυκλικη ενωση CY1121279T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013224093 2013-10-29
PCT/JP2014/005438 WO2015064083A1 (en) 2013-10-29 2014-10-28 Heterocyclic compound

Publications (1)

Publication Number Publication Date
CY1121279T1 true CY1121279T1 (el) 2020-05-29

Family

ID=51932560

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100202T CY1121279T1 (el) 2013-10-29 2019-02-14 Ετεροκυκλικη ενωση

Country Status (18)

Country Link
US (1) US9120777B2 (el)
EP (1) EP3063139B1 (el)
JP (1) JP6450755B2 (el)
AR (2) AR098215A1 (el)
CY (1) CY1121279T1 (el)
DK (1) DK3063139T3 (el)
ES (1) ES2710657T3 (el)
HR (1) HRP20190133T1 (el)
HU (1) HUE041792T2 (el)
LT (1) LT3063139T (el)
PL (1) PL3063139T3 (el)
PT (1) PT3063139T (el)
RS (1) RS58321B1 (el)
SI (1) SI3063139T1 (el)
TR (1) TR201901986T4 (el)
TW (1) TWI668214B (el)
UY (1) UY35801A (el)
WO (1) WO2015064083A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2816032A4 (en) * 2012-02-13 2015-09-30 Takeda Pharmaceutical AROMATIC CORE COMPOUND
WO2014142363A1 (en) * 2013-03-14 2014-09-18 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
JP2023507508A (ja) * 2019-12-19 2023-02-22 ユニヴェルシテ・ドゥ・ストラスブール シグマ－１受容体リガンド及びその使用
CN116354961A (zh) * 2021-12-27 2023-06-30 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
BRPI0408332A (pt) 2003-03-14 2006-03-21 Ono Pharmaceutical Co derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo
AU2004289690A1 (en) 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
CN101506165B (zh) * 2006-08-15 2012-07-04 霍夫曼-拉罗奇有限公司 苯基、吡啶和喹啉衍生物
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
TW200918062A (en) 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
CA2759651A1 (en) 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
WO2014142363A1 (en) 2013-03-14 2014-09-18 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists

Also Published As

Publication number Publication date
TW201542539A (zh) 2015-11-16
TR201901986T4 (tr) 2019-03-21
WO2015064083A1 (en) 2015-05-07
RS58321B1 (sr) 2019-03-29
EP3063139B1 (en) 2018-11-21
PT3063139T (pt) 2019-02-22
AR128158A2 (es) 2024-03-27
JP6450755B2 (ja) 2019-01-09
ES2710657T3 (es) 2019-04-26
AR098215A1 (es) 2016-05-18
SI3063139T1 (sl) 2019-03-29
LT3063139T (lt) 2019-02-25
UY35801A (es) 2015-06-30
DK3063139T3 (en) 2019-03-11
HUE041792T2 (hu) 2019-05-28
JP2016535040A (ja) 2016-11-10
TWI668214B (zh) 2019-08-11
US20150119412A1 (en) 2015-04-30
HRP20190133T1 (hr) 2019-03-22
EP3063139A1 (en) 2016-09-07
PL3063139T3 (pl) 2019-05-31
US9120777B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
CY1121534T1 (el) Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιας
CY1124790T1 (el) Ενωση πεπτιδιου
CY1121279T1 (el) Ετεροκυκλικη ενωση
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
PH12016501614A1 (en) Heterocyclic compound
EA201692219A1 (ru) Способы получения противовирусных соединений
CY1124374T1 (el) Ενωση αρυλαζολιου και παραγοντας ελεγχου παρασιτων
DK3192451T3 (da) Medicinsk krog
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
CY1121163T1 (el) Ανταγωνιστες υποδοχεα σωματοστατινης υποτυπου 5 (sstr5)
CY1123842T1 (el) Ετεροαρυλικες ενωσεις για τη θεραπευτικη αντιμετωπιση οφθαλμικων νοσων
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CY1119583T1 (el) Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα
CY1120142T1 (el) Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης
RU2013142539A (ru) Ароматические полиэфиры
EA201690593A1 (ru) Новые соединения мочевины
MX2015012610A (es) Pacritinib deuterizado.
RU2013134779A (ru) 2-(5-этил-1,3,4-тиадиазолил)амид 2-(4-бромфенил)-4-оксо-4-фенил-2-бутеновой кислоты, обладающий анальгетической активностью
CY1121388T1 (el) Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων
PL400584A1 (pl) Zastosowanie medyczne 3-(tiofen-2-ylo)-1,2,4-triazolo-5-tionu
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями